23 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22771 | Metastatic | Spyridon Sideris | prostate | Bayer | ARASENS | Trial closed | A randomized, double blind, placebo controlled Phase III study of ODM 201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 22935 | Subject was previously enrolled in a selected company-sponsored feeder trial, and has received at least 1 dose of radium-223 dichloride or placebo in the feeder trial. | Géraldine Gebhart | Multiple | Bayer | BAY 88-8223 / 16996 | Trial closed for recruitment | A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride | geraldine.gebhart@hubruxelles.be | 4 | 4 | |
| 28690 | Nieves Martinez Chanza | prostate | AstraZeneca | CAPItello-281 | Trial closed for recruitment | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | ||
| 28883 | Nieves Martinez Chanza | prostate | Exelixis | CONTACT 02 | Trial closed for recruitment | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | ||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22933 | *Histologically confirmed adenocarcinoma of the prostate *Prostate cancer progression documented by PSA according to the Prostate Cancer Working Group 2 (PCWG2) criteria or radiological progression according to RECIST, version 1.1 *Two or more bone meta |
Carlos Artigas Guix | prostate | Bayer | ERA-223 | Trial closed | A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC) | carlos.artigas@hubruxelles.be | 3 | 3 | |
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22676 | 2nd line/ RECIST 1.1/ Biopsy | Thierry Gil | prostate | Janssen | Galahad | Trial closed | A phase 2 efficacy and safety study of Niraparib in men with metastatic castration-resistant prostate cancer and DNA repair anomalies. | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 22760 | Metastatic castration resistant prostate cancer after progression to docetaxel and androgen-receptor targeted agent. | Thierry Gil | prostate | Sanofi-Aventis | LPS14201 ? CARD | Trial closed | A randomized, open label, multicenter study of Cabazitaxel versus an Androgen Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD) | thierry.gil@hubruxelles.be | 3 | 3 |